PD-L1 expression is increased in a subset of basal type breast cancer cells von Soliman, Hatem, Khalil, Farah, Antonia, Scott

Volltext

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study von Hellmann, Matthew D, Dr, Rizvi, Naiyer A, Prof, Goldman, Jonathan W, MD, Gettinger, Scott N, MD, Borghaei, Hossein, DO, Brahmer, Julie R, MD, Ready, Neal E, Prof, Gerber, David E, MD, Chow, Laura Q, MD, Juergens, Rosalyn A, MD, Shepherd, Frances A, Prof, Laurie, Scott A, MD, Geese, William J, PhD, Agrawal, Shruti, PhD, Young, Tina C, MS, Li, Xuemei, MD, Antonia, Scott J, Prof

Volltext

Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies von Passaro, Antonio, Brahmer, Julie, Antonia, Scott, Mok, Tony, Peters, Solange

Volltext

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply von Antonia, Scott J

Volltext

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer von Spigel, David R, Faivre-Finn, Corinne, Gray, Jhanelle E, Vicente, David, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F, Garassino, Marina C, Hui, Rina, Quantin, Xavier, Rimner, Andreas, Wu, Yi-Long, Özgüroğlu, Mustafa, Lee, Ki H, Kato, Terufumi, de Wit, Maike, Kurata, Takayasu, Reck, Martin, Cho, Byoung C, Senan, Suresh, Naidoo, Jarushka, Mann, Helen, Newton, Michael, Thiyagarajah, Piruntha, Antonia, Scott J

Volltext

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study von Antonia, Scott, Prof, Goldberg, Sarah B, MD, Balmanoukian, Ani, MD, Chaft, Jamie E, MD, Sanborn, Rachel E, MD, Gupta, Ashok, MD, Narwal, Rajesh, PhD, Steele, Keith, PhD, Gu, Yu, PhD, Karakunnel, Joyson J, MD, Rizvi, Naiyer A, Prof

Volltext

The NKG2A immune checkpoint — a new direction in cancer immunotherapy von Creelan, Benjamin C., Antonia, Scott J.

Volltext

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial von Antonia, Scott J, Prof, López-Martin, José A, MD, Bendell, Johanna, MD, Ott, Patrick A, MD, Taylor, Matthew, MD, Eder, Joseph Paul, MD, Jäger, Dirk, MD, Pietanza, M Catherine, MD, Le, Dung T, MD, de Braud, Filippo, Prof, Morse, Michael A, Prof, Ascierto, Paolo A, MD, Horn, Leora, MD, Amin, Asim, MD, Pillai, Rathi N, MD, Evans, Jeffry, Prof, Chau, Ian, MD, Bono, Petri, MD, Atmaca, Akin, MD, Sharma, Padmanee, Prof, Harbison, Christopher T, PhD, Lin, Chen-Sheng, PhD, Christensen, Olaf, MD, Calvo, Emiliano, Dr

Volltext

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial von Baas, Paul, Scherpereel, Arnaud, Nowak, Anna K, Fujimoto, Nobukazu, Peters, Solange, Tsao, Anne S, Mansfield, Aaron S, Popat, Sanjay, Jahan, Thierry, Antonia, Scott, Oulkhouir, Youssef, Bautista, Yolanda, Cornelissen, Robin, Greillier, Laurent, Grossi, Francesco, Kowalski, Dariusz, Rodríguez-Cid, Jerónimo, Aanur, Praveen, Oukessou, Abderrahim, Baudelet, Christine, Zalcman, Gérard

Volltext

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 von Ready, Neal, Farago, Anna F., de Braud, Filippo, Atmaca, Akin, Hellmann, Matthew D., Schneider, Jeffrey G., Spigel, David R., Moreno, Victor, Chau, Ian, Hann, Christine L., Eder, Joseph Paul, Steele, Nicola L., Pieters, Anne, Fairchild, Justin, Antonia, Scott J.

Volltext

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study von Gettinger, Scott, Horn, Leora, Jackman, David, Spigel, David, Antonia, Scott, Hellmann, Matthew, Powderly, John, Heist, Rebecca, Sequist, Lecia V, Smith, David C, Leming, Philip, Geese, William J, Yoon, Dennis, Li, Ang, Brahmer, Julie

Volltext

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial von Creelan, Benjamin C., Wang, Chao, Teer, Jamie K., Toloza, Eric M., Yao, Jiqiang, Kim, Sungjune, Landin, Ana M., Mullinax, John E., Saller, James J., Saltos, Andreas N., Noyes, David R., Montoya, Leighann B., Curry, Wesley, Pilon-Thomas, Shari A., Chiappori, Alberto A., Tanvetyanon, Tawee, Kaye, Frederic J., Thompson, Zachary J., Yoder, Sean J., Fang, Bin, Koomen, John M., Sarnaik, Amod A., Chen, Dung-Tsa, Conejo-Garcia, Jose R., Haura, Eric B., Antonia, Scott J.

Volltext

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC von Gray, Jhanelle E., Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Kurata, Takayasu, Chiappori, Alberto, Lee, Ki Hyeong, Cho, Byoung Chul, Planchard, David, Paz-Ares, Luis, Faivre-Finn, Corinne, Vansteenkiste, Johan F., Spigel, David R., Wadsworth, Catherine, Taboada, Maria, Dennis, Phillip A., Özgüroğlu, Mustafa, Antonia, Scott J.

Volltext

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort von Ready, Neal E., Ott, Patrick A., Hellmann, Matthew D., Zugazagoitia, Jon, Hann, Christine L., de Braud, Filippo, Antonia, Scott J., Ascierto, Paolo A., Moreno, Victor, Atmaca, Akin, Salvagni, Stefania, Taylor, Matthew, Amin, Asim, Camidge, D. Ross, Horn, Leora, Calvo, Emiliano, Li, Ang, Lin, Wen Hong, Callahan, Margaret K., Spigel, David R.

Volltext

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer von Hellmann, Matthew D., Callahan, Margaret K., Awad, Mark M., Calvo, Emiliano, Ascierto, Paolo A., Atmaca, Akin, Rizvi, Naiyer A., Hirsch, Fred R., Selvaggi, Giovanni, Szustakowski, Joseph D., Sasson, Ariella, Golhar, Ryan, Vitazka, Patrik, Chang, Han, Geese, William J., Antonia, Scott J.

Volltext

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial von Faivre-Finn, Corinne, Vicente, David, Kurata, Takayasu, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F., Spigel, David R., Garassino, Marina C., Reck, Martin, Senan, Suresh, Naidoo, Jarushka, Rimner, Andreas, Wu, Yi-Long, Gray, Jhanelle E., Özgüroğlu, Mustafa, Lee, Ki H., Cho, Byoung C., Kato, Terufumi, de Wit, Maike, Newton, Michael, Wang, Lu, Thiyagarajah, Piruntha, Antonia, Scott J.

Volltext

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer von Gettinger, Scott, Rizvi, Naiyer A, Chow, Laura Q, Borghaei, Hossein, Brahmer, Julie, Ready, Neal, Gerber, David E, Shepherd, Frances A, Antonia, Scott, Goldman, Jonathan W, Juergens, Rosalyn A, Laurie, Scott A, Nathan, Faith E, Shen, Yun, Harbison, Christopher T, Hellmann, Matthew D

Volltext

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer von Borghaei, Hossein, Gettinger, Scott, Vokes, Everett E, Chow, Laura Q M, Burgio, Marco Angelo, de Castro Carpeno, Javier, Pluzanski, Adam, Arrieta, Oscar, Frontera, Osvaldo Arén, Chiari, Rita, Butts, Charles, Wójcik-Tomaszewska, Joanna, Coudert, Bruno, Garassino, Marina Chiara, Ready, Neal, Felip, Enriqueta, García, Miriam Alonso, Waterhouse, David, Domine, Manuel, Barlesi, Fabrice, Antonia, Scott, Wohlleber, Markus, Gerber, David E, Czyzewicz, Grzegorz, Spigel, David R, Crino, Lucio, Eberhardt, Wilfried Enst Erich, Li, Ang, Marimuthu, Sathiya, Brahmer, Julie

Volltext

Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy von Carbone, David P., Gandara, David R., Antonia, Scott J., Zielinski, Christoph, Paz-Ares, Luis

Volltext

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts von Mediavilla-Varela, Melanie, Boateng, Kingsley, Noyes, David, Antonia, Scott J

Volltext